Literature DB >> 16679760

Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol.

Kurt Stoschitzky1, Gergana Stoschitzky, Helmut Brussee, Claudia Bonelli, Harald Dobnig.   

Abstract

OBJECTIVE: Bisoprolol, carvedilol and nebivolol have been shown to be effective in the treatment of heart failure. However, the beta-blocking effects of these drugs have never been compared directly.
METHODS: Therefore, we performed a randomized, double-blind, placebo-controlled, cross-over trial in 16 healthy males. Subjects received 10 mg bisoprolol, 50 mg carvedilol, 10 mg nebivolol and placebo on the first morning followed by 5 mg bisoprolol once daily, 25 mg carvedilol twice daily, 5 mg nebivolol once daily and placebo for 1 week. Heart rate and blood pressure were measured at rest and exercise 3 and 24 h following intake of the first dose, and immediately before and 3 hours following intake of the last dose of each drug. In addition, effects of the drugs on nocturnal melatonin release were determined, and quality of life (QOL) was evaluated.
RESULTS: Heart rate at exercise was decreased at 3 h following intake of the first single dose of each drug by bisoprolol (-24%), carvedilol (-17%) and nebivolol (-15%), and at 24 h following intake of the respective last dose of each drug following 1 week of chronic administration by bisoprolol (-14%), carvedilol (12 h; -15%) and nebivolol (-13%) (p < 0.05 in all cases). Thus, trough-to-peak-ratios at long-term were as follows: Bisoprolol, 58%; carvedilol (12 h), 85%; nebivolol, 91%. Nocturnal melatonin release was decreased by bisoprolol (-44%, p < 0.05) whereas nebivolol and carvedilol had no effect. QOL with carvedilol was slightly but significantly lower than with the other drugs, whereas bisoprolol and nebivolol did not alter QOL.
CONCLUSIONS: These data show that peak beta-blocking effects of bisoprolol appear stronger than those of nebivolol and carvedilol. On the other hand, nebivolol exerts the highest trough-to-peak-ratio. However, beta-blocking effects of all the three drugs are similar at trough. Only bisoprolol but neither nebivolol nor carvedilol decreased nocturnal melatonin release, a feature which might cause sleep disturbances. Finally, only carvedilol slightly decreased QOL, whereas nebivolol and bisoprolol did not affect QOL. We conclude that different beta-blockers may exert clinically relevant different effects. 2006 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16679760     DOI: 10.1159/000093060

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  19 in total

1.  Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.

Authors:  Frank A J L Scheer; Christopher J Morris; Joanna I Garcia; Carolina Smales; Erin E Kelly; Jenny Marks; Atul Malhotra; Steven A Shea
Journal:  Sleep       Date:  2012-10-01       Impact factor: 5.849

2.  Effects of Heart Failure and its Pharmacological Management on Sleep.

Authors:  Jessica A Jiménez; Barry H Greenberg; Paul J Mills
Journal:  Drug Discov Today Dis Models       Date:  2011

3.  Tachycardia: The hidden cardiovascular risk factor in uncomplicated arterial hypertension.

Authors:  Katarzyna Cierpka-Kmieć; Dagmara Hering
Journal:  Cardiol J       Date:  2019-02-25       Impact factor: 2.737

Review 4.  Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine.

Authors:  David Feldman; Terry S Elton; Doron M Menachemi; Randy K Wexler
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

Review 5.  Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.

Authors:  Maria Marketou; Yashaswi Gupta; Shashank Jain; Panos Vardas
Journal:  Curr Hypertens Rep       Date:  2017-03       Impact factor: 5.369

6.  Aortic elastic properties : effects of carvedilol versus nebivolol.

Authors:  M R Sayin; M Aydin; S M Dogan; T Karabag; M A Cetiner; Z Aktop
Journal:  Herz       Date:  2012-12-23       Impact factor: 1.443

Review 7.  Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.

Authors:  Enrico Agabiti Rosei; Damiano Rizzoni
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Insomnia and chronic heart failure.

Authors:  Don Hayes; Michael I Anstead; Julia Ho; Barbara A Phillips
Journal:  Heart Fail Rev       Date:  2008-08-29       Impact factor: 4.214

9.  Beta-blockers in the treatment of hypertension: new data, new directions.

Authors:  Michael A Weber; George L Bakris; Thomas D Giles; Franz H Messerli
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-03       Impact factor: 3.738

10.  Effects of beta-blockers on archery performance, body sway and aiming behaviour.

Authors:  Emin Ergen; Tahir Hazir; Mesut Celebi; Ayşe Kin-Isler; Serdar Aritan; Volkan Daghan Yaylıoglu; Rustu Guner; Caner Acikada; Alpan Cinemre
Journal:  BMJ Open Sport Exerc Med       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.